| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
San Diego, October 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the third quarter of fiscal year 2026. |
| 13 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
Concerning Notes to be issued pursuant to an Issuing and Paying Agent Agreement dated as of [●] by and between the Issuer and [●], as Issuing and Paying Agent |
| 17 Aug 2026 |
8-K: Other Events
Reference is made to the Indenture dated as of March 12, 2021 (as so supplemented by this Officer’s Certificate, the “Indenture”) by and between Illumina, Inc. (the “Issuer”) and U.S. Bank Trust Company, National Association (as successo... |
| 13 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
as the Administrative Agent, an Issuing Bank, and the Swingline Lender, |
| 12 Aug 2026 |
8-K: Other Events
Illumina, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an a... |
| 07 Aug 2026 |
8-K: Other Events
The Court of Chancery of the State of Delaware authorized this Notice. Thisis not a solicitation from a lawyer. |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the second quarter of fiscal year 2026. |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Eli Lilly and Company’s Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board |
| 26 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 annual meeting of stockholders (the "Annual Meeting") of Illumina, Inc. (the "Company") was held on May 21, 2026, at which the Company's stockholders voted upon the following proposals: |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition; Other Events
San Diego, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the first quarter of fiscal year 2026. |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
David P. King nominated to support next phase of growth and innovation; |
| 05 Feb 2026 |
8-K: Results of Operations and Financial Condition
San Diego, February 5, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the fourth quarter and fiscal year 2025. |
| 30 Jan 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Other Events
Combined capabilities bring high scalability, flexibility, and affordability into protein analysis |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition
San Diego, January 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025 ahead of its presentation at the ... |
| 08 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Veteran genomics leader joins Illumina to advance global medical strategy |
| 25 Nov 2025 |
8-K: Other Events
Reference is made to the Indenture dated as of March 12, 2021 (as so supplemented by this Officer’s Certificate, the “Indenture”) by and between Illumina, Inc. (the “Issuer”) and U.S. Bank Trust Company, National Association (as successo... |
| 12 Nov 2025 |
8-K: Other Events
Illumina, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an a... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
San Diego, October 30, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the third quarter of fiscal year 2025. |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
San Diego, July 31, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the second quarter of fiscal year 2025. |
| 23 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION IS INDICATED BY [* * *]. |
Loading...